CagriSema vs Tirzepatide Trial Completes in Type 2 Diabetes

What the CagriSema vs tirzepatide trial actually tested

The registry record for NCT06221969 describes a randomized phase 3 study sponsored by Novo Nordisk that enrolled 1,024 adults with type 2 diabetes who were already being treated with metformin, either alone or alongside an SGLT2 inhibitor. Participants were assigned by chance, with equal odds, to receive either CagriSema or tirzepatide. The registry lists the participation period as up to about a year and a half per person.

The stated purpose was to measure how much CagriSema lowers blood sugar and body weight relative to tirzepatide in that population. As of the September 4 registry refresh, the study status reads completed, which in ClinicalTrials.gov terms means the final participants have finished their last scheduled visit. It does not mean results are available. No outcome data had been posted to the record at the time of writing.

That distinction matters. A completed status is an administrative milestone, not a readout. Detailed efficacy and safety findings typically arrive later, either through a sponsor announcement, a conference presentation, or a peer-reviewed publication, and the numbers that circulate first are frequently the company's own summary rather than an independently reviewed analysis.

What is CagriSema, and how is it different from semaglutide?

CagriSema is an investigational fixed combination of two injectable compounds. The first is semaglutide, the GLP-1 receptor agonist already marketed as Ozempic for type 2 diabetes and Wegovy for weight management. The second is cagrilintide, a long-acting analog of amylin, a hormone that pancreatic beta cells release alongside insulin and that contributes to satiety and to slowing how quickly the stomach empties.

The rationale behind pairing them is that amylin signaling and GLP-1 signaling act through different pathways, so combining them could produce effects that neither achieves alone. That hypothesis is what the phase 3 program is built to test. The registry record is explicit that CagriSema is a new investigational medicine and that doctors may not yet prescribe it, language worth keeping in mind given how often unapproved compounds surface in gray-market channels.

Tirzepatide, the comparator, is Eli Lilly's dual agonist of the GLP-1 and GIP receptors, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. It is approved and widely prescribed, which is why it functions as an active control rather than a placebo here.

Readers already following a tirzepatide regimen who want to check how their vial concentration maps to syringe units can use the tirzepatide dosage calculator rather than working it out by hand.

Novo Nordisk is also running a recruiting phase 3 study of injectable cagrilintide comparing two versions of the compound against placebo in 285 people with excess body weight.

Cagrilintide on its own is also in phase 3

The same registry update surfaced two separate phase 3 studies of cagrilintide as a standalone treatment rather than as half of a combination. One, NCT07745504, is recruiting 285 participants with excess body weight and compares two different versions of injectable cagrilintide against placebo over roughly nine months. The other, NCT07220759, is listed as active but no longer recruiting, with 330 participants who have overweight or obesity together with type 2 diabetes, randomized two-to-one in favor of active treatment over about a year and a half.

Taken together, these trials indicate that Novo Nordisk is pursuing amylin agonism both as a partner to semaglutide and as an independent line of development. For readers who follow the incretin field, that is the more structurally interesting signal: the next competitive axis in metabolic drug development may not be another incretin receptor added to the stack, but a different hormone system entirely.

Because CagriSema contains semaglutide as one of its two components, people tracking semaglutide separately may find the semaglutide dosage calculator useful for keeping their existing records consistent.

The completed real-world semaglutide study lists an enrollment of 237,211 adults treated under routine clinical practice at their physician's discretion. the completed real-world semaglutide study.

The rest of the registry update: real-world semaglutide and adolescent tirzepatide

Two other records refreshed in the same window are worth noting. Novo Nordisk's real-world study NCT07627074, which assessed weight change in adults treated with commercially available semaglutide under routine clinical care at the treating physician's discretion, is now listed as completed with an enrollment figure of 237,211. Observational studies of that size do not carry the internal validity of a randomized trial, because prescribing is not random and adherence varies, but they capture what happens outside the controlled conditions of a registration trial.

On the Lilly side, SURMOUNT-ADOLESCENTS-2 (NCT06439277) is recruiting 300 adolescents with obesity and multiple weight-related conditions. The registry describes a study lasting roughly 76 weeks with up to 23 visits, evaluating effects on body weight and cardiovascular risk factors alongside a nutrition and physical activity intervention, with an extension of up to 156 additional weeks of treatment for participants continuing from a prior 72-week study.

Trials of this kind typically escalate treatment in stages before reaching a maintenance level, a process explained in our glossary entry on what titration means.

What remains unresolved

The central open question is the actual result. Until data are posted or published, nobody outside the sponsor knows how CagriSema performed against tirzepatide on blood sugar lowering or weight change, or how the two compared on gastrointestinal tolerability, discontinuation rates, and other adverse events. Head-to-head trials against an active, effective comparator are harder to win than placebo-controlled trials, and margins between two strong drugs are usually narrower than cross-trial comparisons suggest.

There is also no approval on the horizon that anyone can point to with a date. Completion of a phase 3 study is one input into a regulatory submission, not a substitute for one. Regulators review the full program, including safety databases assembled across multiple trials, before any decision is made about whether a combination like this reaches the market.

According to the registry record for the head-to-head study, 1,024 adults with type 2 diabetes treated with metformin, with or without an SGLT2 inhibitor, were randomized between CagriSema and tirzepatide.